|Title||Evaluation and Application of Donors with Primary Central Nervous System Tumors|
|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Wu JH, Qiao PF, Sun XY, Dong JH, Liao JX, Liu XY, Gao Z, Lan LG, Li HB, Su QD|
Background: This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations.
Methodology: Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow-up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high-risk group was classified as Group 1, the low-risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor-transmitted CNS tumors was calculated and compared.
Results: The duration from the diagnosis of 29 donors to donation was 5.67 ± 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan-Meier curve showed no significant difference in survival time.
Conclusion: No obvious difference was observed between high-risk and low-risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High-risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.
|Alternate Journal||Clin Transplant.|
|Notify Library Reference ID||4892|